MedPath

A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand

Not Applicable
Completed
Conditions
Corneal Staining
Interventions
Other: Multipurpose Solution #1
Other: Multipurpose Solution #2
Other: Mutlipurpose Solution #3
Other: Multipurpose Solution #4
Registration Number
NCT01335750
Lead Sponsor
Coopervision, Inc.
Brief Summary

This study is a clinical comparison of the biocompatibility of several multipurpose solutions, Renu Fresh, Optifree Replenish, and ClearCare, and saline as a control solution among adapted hydrogel contact lens wearers wearing Avaira (enfilcon A) contact lenses at one research site.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Informed Consent and HIPAA document read, signed, and dated.
  • Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with hydrogel or silicone hydrogel contact lenses.
  • Successfully wearing hydrogel or silicone hydrogel contact lenses on a daily wear basis for at least two weeks prior to the study.
Exclusion Criteria
  • History of hypersensitivity
  • Evidence or history of epithelial herpes simplex keratitis (dendritic keratitis; vaccinia, active or recent varicella, viral disease of the cornea and/or conjunctiva and/or eyelids; bacterial infection of the eye; and/or fungal disease of the eye
  • One functional eye or a monofit eye
  • Ocular conditions such as active acute blepharitis, conjunctival infections, and iritis
  • Type 2 (macropunctate) or greater corneal staining in any region in either eye as observed by slit-lamp at Visit 1 of each study period
  • Sum of the type of corneal staining greater than or equal to 4 across entire cornea in either eye as observed by slit-lamp at Visit 1 of each study period
  • Conjunctival staining covering greater than or equal to 20% in 2 or more corneal regions in either eye as observed by slit-lamp at Visit 1 of each study period
  • Conjunctival injection greater than Grade 2 (moderate-diffuse redness) in either eye as observed by slit-lamp at Visit 1 of each study period
  • Abnormal lenticular opacity in the visual axis of the lens in either eye
  • Use of concomitant topical Rx or over-the-counter (OTC) ocular medications
  • History of seasonal allergies with significant ocular side effects which may have an adverse impact on contact lens wear
  • Pregnant or lactating females

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Multipurpose Solution #4Multipurpose Solution #4Saline Solution
Multipurpose Solution #4Mutlipurpose Solution #3Saline Solution
Multipurpose Solution #3Multipurpose Solution #2Ciba ClearCare Multipurpose Solution
Multipurpose Solution #2Multipurpose Solution #2OptiFree Replenish Multipurpose Solution
Multipurpose Solution #2Mutlipurpose Solution #3OptiFree Replenish Multipurpose Solution
Multipurpose Solution #1Mutlipurpose Solution #3B\&L Renu Fresh Multipurpose Solution
Multipurpose Solution #2Multipurpose Solution #4OptiFree Replenish Multipurpose Solution
Multipurpose Solution #4Multipurpose Solution #1Saline Solution
Multipurpose Solution #1Multipurpose Solution #4B\&L Renu Fresh Multipurpose Solution
Multipurpose Solution #2Multipurpose Solution #1OptiFree Replenish Multipurpose Solution
Multipurpose Solution #1Multipurpose Solution #2B\&L Renu Fresh Multipurpose Solution
Multipurpose Solution #3Multipurpose Solution #1Ciba ClearCare Multipurpose Solution
Multipurpose Solution #3Mutlipurpose Solution #3Ciba ClearCare Multipurpose Solution
Multipurpose Solution #4Multipurpose Solution #2Saline Solution
Multipurpose Solution #1Multipurpose Solution #1B\&L Renu Fresh Multipurpose Solution
Multipurpose Solution #3Multipurpose Solution #4Ciba ClearCare Multipurpose Solution
Primary Outcome Measures
NameTimeMethod
Corneal Staining SeverityBaseline, 2 Hour Period, 4 Hour Period

Severity of staining was recorded for each region using a scale of 0-none to 4-patch \>/=1mm. Analysis of staining was performed by averaging the scores from the five regions for each eye, then identifying the subject's worse eye at each visit. Mean total severity was calcuated from all identified eyes for each visit.

Corneal Staining AreaBaseline, 2 Hour Period, 4 Hour Period

Analysis of staining area was performed by averaging the values from the five regions for each eye and then identifying the subject's worse eye at each visit. Mean total area was calculated from all identified eyes for each visit.

Secondary Outcome Measures
NameTimeMethod
Subjective ComfortVisit 1: Baseline; Visit 2: 2 hours, Visit 3: 4 hours

Subjective comfort ratings 0-100 (0=causes pain, 100=excellent comfort)

Subjective DrynessVisit 1: Baseline; Visit 2: 2 hours, Visit 3: 4 hours

Subjective dryness ratings 0-100 (0=extremely dry, 100=extremely moist)

Trial Locations

Locations (1)

Erdey/Searcy Eye Group

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath